Upstream Bio Inc (UPB)

Currency in USD
2.000
-0.080(-3.85%)
Closed·
1.970-0.030(-1.50%)
·
Advertisement
Trading near 52-week Low
UPB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.0002.190
52 wk Range
2.00033.680
Key Statistics
Prev. Close
2
Open
2.09
Day's Range
2-2.19
52 wk Range
2-33.68
Volume
856.12K
Average Volume (3m)
987.1K
1-Year Change
-91.9872%
Book Value / Share
4.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
UPB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.400
Upside
+970.00%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Upstream Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 21.400
(+970.00% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy18.00+800.00%36.00Maintain11/11/2026
JPMorgan
Hold9.00+350.00%8.00Maintain14/08/2026
Truist Securities
Buy25.00+1,150.00%43.00Maintain12/08/2026
JPMorgan
Hold8.00+300.00%35.00Downgrade12/06/2026
H.C. Wainwright
Buy36.00+1,700.00%-New Coverage03/06/2026

Earnings

Latest Release
10/11/2026
EPS / Forecast
-0.75 / -1.12
Revenue / Forecast
395K / --
EPS Revisions
Last 90 days

Compare UPB to Peers and Sector

Metrics to compare
UPB
Peers
Sector
Relationship
P/E Ratio
−0.7x−1.7x−0.2x
PEG Ratio
0.05−0.150.00
Price/Book
0.5x2.4x2.6x
Price / LTM Sales
38.2x15.5x2.7x
Upside (Analyst Target)
-107.7%72.2%
Fair Value Upside
Unlock2.9%12.4%Unlock

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
20.39M37.20%42.41M
Other Institutional Investors
31.32M57.14%65.14M
Public Companies & Retail Investors
3.11M5.67%6.46M
Total
54.81M100.00%114.01M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
OrbiMed Advisors LLC10.39%5,693,58911,843
FMR LLC6.92%3,793,9307,891

People Also Watch

7.810
TKNO
-0.89%
7.950
CFFN
-1.24%
14.16
MLYS
+2.76%
4.760
EIKN
-7.93%

FAQ

What Is the Upstream Bio (NASDAQ: UPB) Share Price Today?

The Upstream Bio stock price today is 2.000 USD.

What Stock Exchange Does Upstream Bio (UPB) Trade On?

Upstream Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Upstream Bio?

The stock symbol (also called a 'ticker') for Upstream Bio is "UPB."

What Is the Current Upstream Bio Market Capitalisation?

As of today, Upstream Bio (NASDAQ: UPB) market cap is 109.620M USD.

What Is Upstream Bio's (UPB) Earnings Per Share (TTM)?

The Upstream Bio EPS is currently -3.01 (Trailing Twelve Months).

Is UPB a Buy or Sell From a Technical Analyst Perspective?

Based on today's Upstream Bio moving averages and other technical indicators, the daily buy/sell signal for UPB stock is Strong Sell.

How Many Times Has Upstream Bio Stock Split?

Upstream Bio has split 0 times. (See the UPB stock split history page for full effective split date and price information.)

How Many Employees Does Upstream Bio Have?

Upstream Bio has 75 employees, based on their latest Companies House report.

What is the current trading status of Upstream Bio (NASDAQ: UPB)?

As of 20/11/2026, Upstream Bio (UPB) is trading at a share price of 2.000 USD, with a previous close of 2.000 USD. The stock has fluctuated within a day range of 2.000 USD to 2.190 USD, while its 52-week range spans from 2.000 USD to 33.680 USD.

What Is Upstream Bio (UPB) Price Target According to Analysts?

The average 12-month price target for Upstream Bio is 21.400 USD, with a high estimate of 40 USD and a low estimate of 9 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +970.00% Upside potential.

What Is the UPB Premarket Price?

UPB's last pre-market stock price is 2.070 USD. The pre-market share volume is 960.000, and the stock has decreased by -0.010, or -0.480%.

What Is the UPB After Hours Price?

UPB's last after hours stock price is 1.970 USD, the stock has decreased by -0.030, or -1.500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.